We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ARTO:EURONEXT PARISSociete Industrielle & Financiere de l'Artois SA Analysis

Data as of 2026-03-16 - not real-time

IDR 1,360.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Technical indicators suggest a mixed short‑term outlook. The price is trading below both the short‑term and medium‑term moving averages, reinforcing a bearish bias, while the RSI points to an oversold condition and the MACD has turned bullish, hinting at a possible near‑term rebound. Volume has been tapering, which adds pressure on price stability, and the current price sits just above a key support zone, offering a modest cushion.
Fundamentally, the company shows vigorous revenue expansion and solid operating margins, yet valuation metrics are dramatically elevated relative to peers, and cash flow generation is negative. The forward earnings multiple remains far above the industry average, and the absence of dividend payments eliminates income‑based appeal. Analyst sentiment leans toward a buy, but the combination of high volatility, moderate beta, and exposure to Indonesia’s banking regulatory landscape tempers enthusiasm.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • price remains below short‑term moving averages, limiting upside
  • oversold RSI creates potential for a bounce
  • proximity to a defined support level offers downside protection

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • robust revenue growth driven by SME banking expansion
  • operating margins outperform many regional peers
  • analyst consensus is positive with targets above current levels

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • valuation remains stretched relative to earnings fundamentals
  • exposure to Indonesian regulatory and economic environment
  • strong capital base and low leverage support financial stability

Key Metrics & Analysis

Financial Health

Revenue Growth36.30%
Profit Margin13.46%
P/E Ratio84.1
ROE3.19%
ROA0.85%
P/B Ratio2.1
Op. Cash FlowIDR-5274880966656
Industry P/E16.5

Technical Analysis

TrendBearish
RSI35.1
SupportIDR 1,300.00
ResistanceIDR 1,720.00
MA 20IDR 1,522.50
MA 50IDR 1,709.10
MA 200IDR 1,924.35
MACDBullish
VolumeDecreasing
Fear & Greed Index79.45

Valuation

Target PriceIDR 2,412.00
Upside/Downside77.35%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.62
Volatility59.99%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskHigh
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.